Literature DB >> 24890909

Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.

Gabriel Mannis1, Davina Wu, Tiffany Dea, Theodora Mauro, Gerald Hsu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24890909      PMCID： PMC4548957          DOI： 10.1002/ajh.23775

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  3 in total

1.  Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

Authors:  Susan O'Brien; Richard R Furman; Steven E Coutre; Jeff P Sharman; Jan A Burger; Kristie A Blum; Barbara Grant; Donald A Richards; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Raquel Izumi; Ahmed Hamdy; Betty Y Chang; Thorsten Graef; Fong Clow; Joseph J Buggy; Danelle F James; John C Byrd
Journal:  Lancet Oncol       Date:  2013-12-10       Impact factor: 41.316

2.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

3.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245
  3 in total
  6 in total

1.  Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.

Authors:  Carole Bitar; Mohammed Z H Farooqui; Janet Valdez; Nakhle S Saba; Susan Soto; Amanda Bray; Gerald Marti; Adrian Wiestner; Edward W Cowen
Journal:  JAMA Dermatol       Date:  2016-06-01       Impact factor: 10.282

2.  Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.

Authors:  Philipp Haselmayer; Montserrat Camps; Lesley Liu-Bujalski; Ngan Nguyen; Federica Morandi; Jared Head; Alison O'Mahony; Simone C Zimmerli; Lisa Bruns; Andrew T Bender; Patricia Schroeder; Roland Grenningloh
Journal:  J Immunol       Date:  2019-04-15       Impact factor: 5.422

3.  Outcomes of Reduced Frequency Dosing of Ibrutinib in Chronic Lymphocytic Leukemia Patients Following Complete or Partial Remission: A Pilot Study.

Authors:  William Alexander; Sarah Davis; Raj Ramakrishna; Arumugam Manoharan
Journal:  J Hematol       Date:  2020-08-14

4.  Ibrutinib-Associated Skin Toxicity: A Case of Maculopapular Rash in a 79-Year Old Caucasian Male Patient with Relapsed Waldenstrom's Macroglobulinemia and Review of the Literature.

Authors:  Anders Bisgaard Jensen; Birgitte Stausbøl-Grøn; Rikke Riber-Hansen; Francesco d'Amore
Journal:  Dermatol Reports       Date:  2017-04-20

5.  Ibrutinib-Associated Nail Plate Abnormalities: Case Reports and Review.

Authors:  Lucas A Heldt Manica; Philip R Cohen
Journal:  Drug Saf Case Rep       Date:  2017-11-01

6.  Ibrutinib-associated pityriasis rosea-like rash.

Authors:  Carole Bitar; Azeen Sadeghian; Lacey Sullivan; Andrea Murina
Journal:  JAAD Case Rep       Date:  2017-12-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.